Team

Jackie has over 35 years of experience of working in & knowledge of the global biotech & pharmaceutical industry, primarily in the commercial & strategy fields. Her company, Plexsus Consulting Services, has worked with start-up companies and larger biotech's, in multiple therapy areas, to identify and negotiate deals for the commercialisation of single assets or sale of companies. Jackie was Commercial Director for GeneMedix (GMX) plc, where she was part of the team who completed a dual float on the London and Singapore Stock Exchanges. She has worked for PA Consulting Group, Novo Nordisk A/S, Boehringer Ingelheim and Warner Lambert. Jackie has served on the Board of Imophoron Ltd, Carbometrics Ltd and CanImGuide Therapeutics AB.

As a translational researcher for the last 32 years and Professor at Universities of Bristol, Nottingham and Pretoria, Prof Bates has spun out three companies based on his discoveries, and as Founding Director of the University of Nottingham Centre for Cancer Sciences from 2017 to 2023 has run strategic initiatives that cross multiple disciplines. David co-founded Exonate Ltd (2013), a Cambridge based clinical stage company developing anti-angiogenic eye drops where he was the Chief Scientific Officer until 2022. He has acted as a scientific advisor to major pharmaceutical companies including Pfizer, Takeda and Alcon. His academic research has contributed to the development of therapeutics in vascular eye disease and in cancer through collaborations with Roche and Astra Zeneca. He has published more than 200 papers and is the inventor on 13 patents.

Robin is a Fellow of the Institute of Chartered Accountants of England & Wales. He has expertise in all aspects of corporate finance, fundraising experience from Startup, Series A/B/B+ to IPO and significant experience in working with Private Equity, Institutional and Venture Capital investors. He has worked for multiple companies in the Tech, Life Sciences and Manufacturing sectors including Imspex Diagnostics, Purespring Therapeutics, NanoMab, Aqualisa Products and Bio Products Laboratory.

Gary is an experienced C-level leader and drug developer across all phases of drug development (Phase 1 – 4) including NCE’s, biologics, repurposing of drugs as well as early development experience in cell based therapies. He has over 20 years’ experience across a broad range of diseases and therapeutic areas and extensive experience in negotiations with Regulatory Agencies (e.g. FDA, EMA and PMDA).

Gary is recognised as an international expert in pulmonary disease (including pulmonary hypertension and asthma) and hepatology (including infectious diseases, cirrhosis/portal hypertension and NASH (now MASH)/liver fibrosis) with expertise in evaluating drug-induced liver disease. He has extensive clinical experience as an internist in infectious diseases, intensive care and gastro-enterology/hepatology.

He has worked for Pfizer, Aerami Therapeutics Inc, Vectura Ltd and Conatus Pharmaceuticals.

Amanda has over 20 years’ experience on the sell side having previously worked at a range of institutions including NatWest Markets, CIBC and Credit Suisse, within US Institutional Equities and Capital Markets. Amanda’s also has recent experience within investor relations, roadshow logistics, office manager and event planning.

Kishor has directed and managed biotherapeutic development programs from early pre-clinical stage through IND/IMPD enabling studies and into clinical development. He has over 23 years CMC drug life-cycle management experience, effectively translating strategic development plans into operational projects satisfying ICH guidelines for approval in USA and the EU. He is adept at managing cross-function teams and leading technical discussions with contractors and employees in analytics, process development, cGMP manufacturing and fill/finish. He has worked with start-ups and SMEs developing biologics and biosimilars of diverse nature; peptides, complex glycoproteins, including antibodies, and more recently cell and gene therapies.

Kevin has worked in the pharma and biotech industry for over 18 years, primarily operating in the discovery and preclinical development phases of medicine development. Kevin has worked previously at Cytoseek, UCB, Roche, Bicycle Therapeutics and Pfizer. His expertise is in the realm of biologics and ATMP drug development, across a variety of therapeutic areas, including oncology, ophthalmology, neurodegeneration, cardiovascular, pain, anti-infectives and autoimmune diseases. In his previous roles he has also led development of regulatory strategies and coordinated cross-industry working groups focusing on regulatory aspects of biologics development. He is currently an independent consultant with a passion for helping biotech companies such as IsomAb to deliver promising new medicines to patients who suffer from severe debilitating diseases with limited or no treatment options.

Chris has worked in the pharmaceutical and biotech industries in pre-clinical and clinical development for over 20 years starting at Bayer, Fisons Pharma, Xenova, Onyvax and later Development Director at MorEx Development Partners, Executive Director of Global Drug Development at PRA Health Sciences. He has experience working in a number of therapeutic areas with both small molecules and biologics. He has broad expertise in pre-clinical and clinical development and regulatory affairs with multiple Regulatory Agencies, including the MHRA and the FDA.

Dami has worked in the biotech industry for over 10 years with a major focus on stem cell biology, molecular biology, and laboratory management. He is a chartered biologist with a Master’s degree from the University of Bristol. His expertise covers the setup and running of laboratories in Human Tissue Authority and Medicine and Healthcare products Regulatory Agency licensed facilities; he brings a wealth of experience in the implementation of Good Laboratory Practice and Quality Management Systems. Dami has commercial experience working for Brooks Life Sciences, providing global support and launching life science products as a Product Manager. This experience combined with his laboratory experience has enabled him to lead, as a Director level, at two start-up companies, Circular 1 Health and DAM Health; both of which attained UKAS (National Accreditation Body for the United Kingdom) accreditations.

Christine has worked in the pharmaceutical and biotech industries in R&D for over 25 years, starting at Ciba-Geigy (now Novartis in Switzerland), British Biotechnology Ltd; Glaxo Institute for Molecular Biology, Serono and later Director of Protein Engineering and Antibody Therapeutics at Merck Serono (part Merck KGaA), Head of Antibody Discovery at Arsanis Biosciences, and most recently Head of Antibody Therapeutics at GSK until 2020. She has experience working in a variety of therapeutic areas including cancer, cardiovascular, autoimmune and inflammatory diseases and infectious diseases. She has broad expertise in the discovery, pre-clinical development and evaluation of therapeutic proteins and monoclonal antibodies. Christine has an excellent track record of innovation and productivity in research witnessed by inventorship on over 40 patent applications and is author of over 80 scientific papers.